Top Markets
#1 ADO Protocol ADO Protocol +328.82%
#2 GoPlus Security GoPlus Security +57.25%
#3 Starpower Starpower +44.49%
#4 Tutorial Tutorial +34.66%
#5 Verus Coin Verus Coin +33.62%
#6 Nockchain Nockchain +31.92%
#7 Chainflip Chainflip +28.11%
#8 The Black Bull The Black Bull +25.66%
#9 GAIB AID GAIB AID +24.67%
#10 Casper Network Casper Network +16.94%
Coin of the day
ADO Protocol ADO Protocol
설정
언어
한국어
통화
USD
테마
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

4598
주식 순위 #32530
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
주가
$0.69158324
시가총액
$9.84M
변동 (1일)
0.00%
변동 (1년)
-84.15%
국가
JP
거래 Delta-Fly Pharma, Inc. (4598)

카테고리

Healthcare
Delta-Fly Pharma, Inc. (4598)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Delta-Fly Pharma, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Delta-Fly Pharma, Inc.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE